López-Campos Fernando, Conde-Moreno Antonio, Barrado Los Arcos Marta, Gómez-Caamaño Antonio, García-Gómez Raquel, Hervás Morón Asunción
Deparment Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Deparment Radiation Oncology, Hospital Universitario y Politécnico La Fe, 46010 Valencia, Spain.
J Pers Med. 2021 Nov 12;11(11):1190. doi: 10.3390/jpm11111190.
The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients-androgen deprivation therapy (ADT) alone-until metastatic progression is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits-including significantly better overall survival (OS)-for treatments that combine ADT with apalutamide, enzalutamide, and darolutamide. As a result, these approaches are now included in treatment guidelines and are considered a standard of care. In the present article, we discuss the changing landscape of the management of patients with nmCRPC.
非转移性去势抵抗性前列腺癌（nmCRPC）的治疗是一项尚未得到充分满足的重大医疗需求。对于这些患者，经典的治疗方法——仅采用雄激素剥夺疗法（ADT）直至出现转移进展——现在被认为并非最佳选择。多项随机III期临床试验表明，将ADT与阿帕鲁胺、恩杂鲁胺和达罗他胺联合使用的治疗方法具有显著的临床益处，包括显著延长总生存期（OS）。因此，这些方法现已被纳入治疗指南，并被视为一种标准治疗方案。在本文中，我们将探讨nmCRPC患者管理的不断变化的格局。
